Sen. Grassley Considering Hearings On Safety Of Sanofi-Aventis’ Ketek
This article was originally published in The Pink Sheet Daily
Executive Summary
The threat follows a meeting with FDA officials that the Finance Committee Chairman found unsatisfactory due to the absence of a line investigator involved with the agency’s scrutiny of the drug.
You may also be interested in...
Sanofi’s Ketek Gets December Advisory Committee Review
Two-day meeting expected to focus on safety issues related to the antibiotic, which has been associated with liver injury.
Sanofi’s Ketek Gets December Advisory Committee Review
Two-day meeting expected to focus on safety issues related to the antibiotic, which has been associated with liver injury.
Ketek Risk Cannot Be Distinguished From Class, FDA Says
Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.